Drug-drug Interaction Study With ASP1941 and Glimepiride

Sponsor
Astellas Pharma Inc (Industry)
Overall Status
Completed
CT.gov ID
NCT01302158
Collaborator
(none)
52
1
4
13.1

Study Details

Study Description

Brief Summary

A study to investigate the effect of ASP1941 on the pharmacokinetics and safety of glimepiride (Part A) and to investigate the effect of glimepiride on the pharmacokinetics, safety and pharmacodynamics of ASP1941 (Part B).

Condition or Disease Intervention/Treatment Phase
Phase 1

Detailed Description

Study includes two parts. Part A is to investigate the effect of multiple oral doses of ASP1941 on the pharmacokinetics of glimepiride, and Part B is to investigate the effect of multiple oral doses of glimepiride on the pharmacokinetics of ASP1941.

Study Design

Study Type:
Interventional
Actual Enrollment :
52 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
An Open-label, Randomized Crossover Study to Evaluate the Effect of ASP1941 on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glimepiride in Healthy Subjects and Vice Versa
Study Start Date :
Dec 1, 2009
Actual Primary Completion Date :
Apr 1, 2010
Actual Study Completion Date :
Apr 1, 2010

Outcome Measures

Primary Outcome Measures

  1. Effect of multiple doses of ASP1941 on the Pharmacokinetics of glimepiride [14 days]

Secondary Outcome Measures

  1. Effect of multiple doses of glimepiride on the Pharmacokinetics of ASP1941 [14 days]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 55 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • BMI between 18.5 and 30 kg/m2, inclusive
Exclusion Criteria:
  • Any of the liver function tests above the upper limit of normal

  • Pulse <40 or >90 bpm; Systolic Blood Pressure >140 mmHg; Diastolic Blood Pressure > 90 mmHg

Contacts and Locations

Locations

Site City State Country Postal Code
1 Groningen Netherlands 9470 AE

Sponsors and Collaborators

  • Astellas Pharma Inc

Investigators

  • Study Director: Use Central Contact, Astellas Pharma Europe B.V.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT01302158
Other Study ID Numbers:
  • 1941-CL-0059
  • 2009-013172-50
First Posted:
Feb 23, 2011
Last Update Posted:
Feb 23, 2011
Last Verified:
Feb 1, 2011
Keywords provided by , ,
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 23, 2011